Literature DB >> 25743118

Antinociceptive activity of transient receptor potential channel TRPV1, TRPA1, and TRPM8 antagonists in neurogenic and neuropathic pain models in mice.

Kinga Sałat1, Barbara Filipek.   

Abstract

The aim of this research was to assess the antinociceptive activity of the transient receptor potential (TRP) channel TRPV1, TRPM8, and TRPA1 antagonists in neurogenic, tonic, and neuropathic pain models in mice. For this purpose, TRP channel antagonists were administered into the dorsal surface of a hind paw 15 min before capsaicin, allyl isothiocyanate (AITC), or formalin. Their antiallodynic and antihyperalgesic efficacies after intraperitoneal administration were also assessed in a paclitaxel-induced neuropathic pain model. Motor coordination of paclitaxel-treated mice that received these TRP channel antagonists was investigated using the rotarod test. TRPV1 antagonists, capsazepine and SB-366791, attenuated capsaicin-induced nociceptive reaction in a concentration-dependent manner. At 8 µg/20 µl, this effect was 51% (P<0.001) for capsazepine and 37% (P<0.05) for SB-366791. A TRPA1 antagonist, A-967079, reduced pain reaction by 48% (P<0.05) in the AITC test and by 54% (P<0.001) in the early phase of the formalin test. The test compounds had no influence on the late phase of the formalin test. In paclitaxel-treated mice, they did not attenuate heat hyperalgesia but N-(3-aminopropyl)-2-{[(3-methylphenyl)methyl]oxy}-N-(2-thienylmethyl) benzamide hydrochloride salt (AMTB), a TRPM8 antagonist, reduced cold hyperalgesia and tactile allodynia by 31% (P<0.05) and 51% (P<0.01), respectively. HC-030031, a TRPA1 channel antagonist, attenuated tactile allodynia in the von Frey test (62%; P<0.001). In conclusion, distinct members of TRP channel family are involved in different pain models in mice. Antagonists of TRP channels attenuate nocifensive responses of neurogenic, tonic, and neuropathic pain, but their efficacies strongly depend on the pain model used.

Entities:  

Keywords:  Allyl isothiocyanate; Capsaicin; Formalin; Neurogenic pain; Paclitaxel-induced sensory neuropathy; Transient receptor potential channels

Mesh:

Substances:

Year:  2015        PMID: 25743118      PMCID: PMC4357366          DOI: 10.1631/jzus.B1400189

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  45 in total

1.  Antinociceptive effect of three common analgesic drugs on peripheral neuropathy induced by paclitaxel in rats.

Authors:  David Pascual; Carlos Goicoechea; Elisa Burgos; María Isabel Martín
Journal:  Pharmacol Biochem Behav       Date:  2010-02-23       Impact factor: 3.533

2.  Effects of xaliproden, a 5-HT₁A agonist, on mechanical allodynia caused by chemotherapeutic agents in mice.

Authors:  Tsugunobu Andoh; Ayumi Sakamoto; Yasushi Kuraishi
Journal:  Eur J Pharmacol       Date:  2013-09-23       Impact factor: 4.432

3.  Analgesic, antioedematous and antioxidant activity of γ-butyrolactone derivatives in rodents.

Authors:  Kinga Salat; Tadeusz Librowski; Andrzej Moniczewski; Krystyna Stanisz-Wallis; Krzysztof Wieckowski; Barbara Malawska
Journal:  Behav Pharmacol       Date:  2012-08       Impact factor: 2.293

4.  AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome.

Authors:  Erin S R Lashinger; Matthew S Steiginga; J Paul Hieble; Lisa A Leon; Scott D Gardner; Rakesh Nagilla; Elizabeth A Davenport; Bryan E Hoffman; Nicholas J Laping; Xin Su
Journal:  Am J Physiol Renal Physiol       Date:  2008-06-18

5.  Analgesic activity of 3-mono-substituted derivatives of dihydrofuran-2-one in experimental rodent models of pain.

Authors:  Kinga Sałat; Barbara Filipek; Krzysztof Wieckowski; Barbara Malawska
Journal:  Pharmacol Rep       Date:  2009 Sep-Oct       Impact factor: 3.024

Review 6.  Animal models of chemotherapy-evoked painful peripheral neuropathies.

Authors:  Nicolas Authier; David Balayssac; Fabien Marchand; Bing Ling; Aude Zangarelli; Juliette Descoeur; François Coudore; Emmanuel Bourinet; Alain Eschalier
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

7.  The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain.

Authors:  Katharine M Walker; Laszlo Urban; Stephen J Medhurst; Sadhana Patel; Mohanjit Panesar; Alyson J Fox; Peter McIntyre
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

8.  Transient receptor potential vanilloid 4 is essential in chemotherapy-induced neuropathic pain in the rat.

Authors:  Nicole Alessandri-Haber; Olayinka A Dina; Jenny J Yeh; Carlos A Parada; David B Reichling; Jon D Levine
Journal:  J Neurosci       Date:  2004-05-05       Impact factor: 6.167

9.  Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception.

Authors:  Tinna M Laughlin; Kevin V Tram; George L Wilcox; Angela K Birnbaum
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

10.  The pungent substances piperine, capsaicin, 6-gingerol and polygodial inhibit the human two-pore domain potassium channels TASK-1, TASK-3 and TRESK.

Authors:  Leopoldo R Beltrán; Corinna Dawid; Madeline Beltrán; Guenter Gisselmann; Katharina Degenhardt; Klaus Mathie; Thomas Hofmann; Hanns Hatt
Journal:  Front Pharmacol       Date:  2013-11-18       Impact factor: 5.810

View more
  32 in total

Review 1.  TRPs and pain.

Authors:  Yi Dai
Journal:  Semin Immunopathol       Date:  2015-09-15       Impact factor: 9.623

Review 2.  Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives.

Authors:  Robson da Costa; Giselle F Passos; Nara L M Quintão; Elizabeth S Fernandes; João Raphael L C B Maia; Maria Martha Campos; João B Calixto
Journal:  Br J Pharmacol       Date:  2020-06-03       Impact factor: 8.739

3.  Antinociceptive, antiedematous, and antiallodynic activity of 1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione derivatives in experimental models of pain.

Authors:  Anna Dziubina; Dominika Szkatuła; Joanna Gdula-Argasińska; Magdalena Kotańska; Barbara Filipek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-19       Impact factor: 3.000

4.  TRPV1-Targeted Drugs in Development for Human Pain Conditions.

Authors:  Mircea Iftinca; Manon Defaye; Christophe Altier
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

5.  The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4.

Authors:  Yan Li; Pavel Adamek; Haijun Zhang; Claudio Esteves Tatsui; Laurence D Rhines; Petra Mrozkova; Qin Li; Alyssa K Kosturakis; Ryan M Cassidy; Daniel S Harrison; Juan P Cata; Kenneth Sapire; Hongmei Zhang; Ross M Kennamer-Chapman; Abdul Basit Jawad; Andre Ghetti; Jiusheng Yan; Jiri Palecek; Patrick M Dougherty
Journal:  J Neurosci       Date:  2015-09-30       Impact factor: 6.167

6.  A Human TRPA1-Specific Pain Model.

Authors:  Stefan Heber; Markus Gold-Binder; Cosmin I Ciotu; Martin Witek; Nino Ninidze; Hans-Georg Kress; Michael J M Fischer
Journal:  J Neurosci       Date:  2019-03-12       Impact factor: 6.167

Review 7.  Pain transduction: a pharmacologic perspective.

Authors:  Dan M McEntire; Daniel R Kirkpatrick; Nicholas P Dueck; Mitchell J Kerfeld; Tyler A Smith; Taylor J Nelson; Mark D Reisbig; Devendra K Agrawal
Journal:  Expert Rev Clin Pharmacol       Date:  2016-05-23       Impact factor: 5.045

8.  Antinociceptive effect of two novel transient receptor potential melastatin 8 antagonists in acute and chronic pain models in rat.

Authors:  Carmen De Caro; Roberto Russo; Carmen Avagliano; Claudia Cristiano; Antonio Calignano; Andrea Aramini; Gianluca Bianchini; Marcello Allegretti; Laura Brandolini
Journal:  Br J Pharmacol       Date:  2018-04-14       Impact factor: 8.739

Review 9.  Molecular Targets of Cannabidiol in Neurological Disorders.

Authors:  Clementino Ibeas Bih; Tong Chen; Alistair V W Nunn; Michaël Bazelot; Mark Dallas; Benjamin J Whalley
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

10.  Antinociceptive and genotoxic assessments of the antagonist TRPV1 receptor SB-366791 on morphine-induced tolerance in mice.

Authors:  Thiago Kastell Mazeto; Jaqueline Nascimento Picada; Áurea Pandolfo Correa; Isadora Nunes Rebelo; Magali Terra Ribeiro; Marcus Vinícius Gomez; Alessandra Hubner de Souza
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-10-26       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.